News

05/03/2012 - Argos Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Arcelis™ Personalized Immunotherapy


Read More »

05/02/2012 - EKOS Corporation Announces Two More Pulmonary Embolism Clinical Studies


Read More »

04/24/2012 - Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012


Read More »